Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo and Radiation in Chemotherapy-Ineligible Urothelial Bladder Cancer
NCT03421652Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Apr 2018
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in bladder urothelial carcinoma, sponsored by Barbara Ann Karmanos Cancer Institute. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03421652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421652.